1
Participants
Start Date
October 31, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
Ranibizumab
Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
Casey Eye Institute, Portland
Collaborators (1)
Genentech, Inc.
INDUSTRY
Oregon Health and Science University
OTHER